Robert Chang, Chairman

Currently the President and CEO of Myra Medical, Mr. Chang has more than 30 years of executive and development experience, predominantly in structural heart therapies. Prior to joining Myra, Chang was President and CEO of MVRx, Inc. and prior to that the Executive Vice President and Chief Technology Officer of Sadra Medical prior to its acquisition by Boston Scientific Corporation. Previous to Sadra, Robert co-founded and served as President, CEO and Director of Ample Medical. In the past, Mr. Chang held positions of increasing responsibility at Satiety, IsoStent and Devices for Vascular Intervention. Robert holds a BS from Cal Poly and an MS from MIT both in Mechanical Engineering.

Doug Koo, Board Member

Doug serves as CFO and Managing Director of Ajax Health. He also serves as the CFO of current Ajax companies Ablacon and Verix Health and is a Managing Director of EPMap-System. He has over 25 years of experience in management consulting and as an executive of venture-backed companies.

Prior to Ajax, Doug was the CFO of EPIX Therapeutics, which was acquired by Medtronic in 2019, the CFO of Spirox, which was acquired by Entellus in 2017, and the CFO of CV Ingenuity, which was acquired by Covidien in 2013. Prior to CV Ingenuity, Doug served as CFO and CEO at several high-tech and healthcare services companies. Doug began his professional career as a management consultant at Gemini Consulting. Doug also currently serves on the Board of Bear Cloud Technologies.

Doug received an M.B.A. from Stanford University and a B.A. from UC San Diego.

Lifei Cheng, Board Member

Lifei Cheng is the Founder & CEO of MedTecX, a global medtech accelerator based in China.Previously, Mr. Cheng was the Vice President of Business Development & Ventures at Medtronic and led strategic investments and the integration of Covidien into Medtronic in Greater China. Cheng founded and managed the Medtronic-Sequoia China ventures, a $60 million fund dedicated to investments in medical technology and service startups and started three new ventures that scaled into new businesses and growth platforms.

Prior to that, Lifei led Business Development at MSD / Merck China where he built and led a cross function and cross border team to generate profitable growth through local investment and partnership, including the Joint Venture with Simcere. Mr. Cheng’s career at Merck began in the United States where headed a Portfolio Management group for Merck's R&D pipeline.

Lifei holds an executive MBA from The Wharton School, a Ph.D. in Engineering and Economics from Carnegie Mellon University and dual B.S. degrees in Engineering and Business from Tsinghua University.